Slingshot members are tracking this event:
Celldex's (CLDX) Phase 2b METRIC Study glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Apr 16, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Metric Study, Glembatumumab Vedotin, Xeloda, (capecitabine)